The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today ...

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.

GENT, Belgium & MALVERN, Pa. & TOKYO, January 28, 2026--(BUSINESS WIRE)--H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 ...

GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G pTau 217 CSF assay for the fully automated ...

BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidelines NOVATO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

At the intersection of buzzy wellness and beauty is red light therapy. We’ve seen the overlap reach an overwhelming number of launches, from LED face masks and hair-growth helmets to large panel lamps ...

This is an important study that identifies the developmental time window during which re-expression of TCF4 mutated in Pitt-Hopkins syndrome, can rescue phenotypic features of brain function in a TCF4 ...

Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial ...

Background Physical activity has been associated with neuroprotective and immunomodulatory benefits, potentially influencing ...